We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead Ramps Up Remdesivir Production as More Trials Emerge
Gilead Ramps Up Remdesivir Production as More Trials Emerge
Gilead CEO Daniel O’Day announced that the company is ramping up production of its antiviral remdesivir for COVID-19 and hopes to have 500,000 treatment courses by October, and more than 1 million treatment courses by the end of the year.